PTPRC and neoplasm: CHCs are detected at substantially higher numbers than circulating tumor cells (CTCs) in patients with UM.(9) This is important as low levels of conventionally defined CTCs (those that lack the immune marker CD45) have limited use as a viable biomarker in patients with UM.